RxSight, Inc. (NASDAQ:RXST) Shares Acquired by Swiss National Bank

Swiss National Bank raised its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 2.6% during the 4th quarter, Holdings Channel reports. The fund owned 66,300 shares of the company’s stock after purchasing an additional 1,700 shares during the period. Swiss National Bank’s holdings in RxSight were worth $2,279,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Quest Partners LLC increased its stake in RxSight by 346.1% during the 3rd quarter. Quest Partners LLC now owns 3,069 shares of the company’s stock valued at $152,000 after buying an additional 2,381 shares during the period. Intech Investment Management LLC acquired a new position in shares of RxSight during the third quarter valued at approximately $598,000. Charles Schwab Investment Management Inc. increased its stake in shares of RxSight by 28.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 285,329 shares of the company’s stock valued at $14,104,000 after acquiring an additional 62,507 shares during the period. Larson Financial Group LLC raised its holdings in RxSight by 55.8% during the third quarter. Larson Financial Group LLC now owns 1,536 shares of the company’s stock worth $76,000 after purchasing an additional 550 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in RxSight in the third quarter worth approximately $605,000. 78.78% of the stock is currently owned by institutional investors.

Insider Buying and Selling at RxSight

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the transaction, the director now owns 24,793 shares in the company, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jesse Anderson Corley bought 1,443 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was purchased at an average cost of $31.18 per share, for a total transaction of $44,992.74. Following the completion of the transaction, the director now owns 1,443 shares in the company, valued at approximately $44,992.74. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 9.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price objective on shares of RxSight in a research note on Wednesday, February 26th. JPMorgan Chase & Co. reduced their price objective on shares of RxSight from $62.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Wells Fargo & Company lowered their price objective on shares of RxSight from $40.00 to $35.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. UBS Group assumed coverage on shares of RxSight in a report on Friday, December 6th. They set a “buy” rating and a $52.00 target price for the company. Finally, Stifel Nicolaus decreased their price target on shares of RxSight from $33.00 to $28.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.33.

RxSight Stock Performance

NASDAQ RXST opened at $26.67 on Friday. The firm’s 50 day moving average price is $29.18 and its two-hundred day moving average price is $39.35. RxSight, Inc. has a twelve month low of $24.09 and a twelve month high of $66.54. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -32.13 and a beta of 1.22.

RxSight (NASDAQ:RXST) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). The business had revenue of $40.21 million for the quarter, compared to analysts’ expectations of $40.23 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. On average, research analysts forecast that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.